BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 29222300)

  • 21. Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.
    Bianchi G; Anderson KC
    CA Cancer J Clin; 2014; 64(6):422-44. PubMed ID: 25266555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging biological insights and novel treatment strategies in multiple myeloma.
    Gentile M; Recchia AG; Mazzone C; Morabito F
    Expert Opin Emerg Drugs; 2012 Sep; 17(3):407-38. PubMed ID: 22920042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma.
    D'Agostino M; Gazzera G; Cetani G; Bringhen S; Boccadoro M; Gay F
    Curr Med Chem; 2019; 26(32):5968-5981. PubMed ID: 29756564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies.
    McCullough KB; Hobbs MA; Abeykoon JP; Kapoor P
    Curr Hematol Malig Rep; 2018 Apr; 13(2):114-124. PubMed ID: 29450683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple myeloma.
    Röllig C; Knop S; Bornhäuser M
    Lancet; 2015 May; 385(9983):2197-208. PubMed ID: 25540889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma.
    Cook G; Zweegman S; Mateos MV; Suzan F; Moreau P
    Crit Rev Oncol Hematol; 2018 Jan; 121():74-89. PubMed ID: 29279102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Tao of myeloma.
    Boise LH; Kaufman JL; Bahlis NJ; Lonial S; Lee KP
    Blood; 2014 Sep; 124(12):1873-9. PubMed ID: 25097176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging therapies targeting the ubiquitin proteasome system in cancer.
    Weathington NM; Mallampalli RK
    J Clin Invest; 2014 Jan; 124(1):6-12. PubMed ID: 24382383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.
    Le Ray E; Jagannath S; Palumbo A
    Expert Rev Hematol; 2016 Jan; 9(1):91-105. PubMed ID: 26558304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Diagnostic and therapeutic considerations on recurrence of multiple myeloma : A current overview].
    Kortüm KM; Einsele H
    Internist (Berl); 2019 Jan; 60(1):34-41. PubMed ID: 30536028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma.
    Jelinek T; Paiva B; Hajek R
    Front Immunol; 2018; 9():2431. PubMed ID: 30505301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
    Ashjian E; Redic K
    J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Multiple myeloma: pathophysiology and progress in management].
    Kuroda J; Chinen Y
    Rinsho Ketsueki; 2017; 58(5):487-497. PubMed ID: 28592764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Seeking Convergence and Cure with New Myeloma Therapies.
    Choudhry P; Galligan D; Wiita AP
    Trends Cancer; 2018 Aug; 4(8):567-582. PubMed ID: 30064664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives.
    Lonial S; Durie B; Palumbo A; San-Miguel J
    Leukemia; 2016 Mar; 30(3):526-35. PubMed ID: 26265184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.
    Su CT; Ye JC
    J Hematol Oncol; 2021 Jul; 14(1):115. PubMed ID: 34301270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Novel targeted therapy in multiple myeloma].
    Izumi T
    Nihon Rinsho; 2014 Jun; 72(6):1089-93. PubMed ID: 25016809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting BCMA in Multiple Myeloma.
    Tan CR; Shah UA
    Curr Hematol Malig Rep; 2021 Oct; 16(5):367-383. PubMed ID: 34432234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kidney Transplant in the Era of Modern Therapy for Multiple Myeloma.
    Huskey JL; Heilman RL; Khamash H; Fonseca R
    Transplantation; 2018 Dec; 102(12):1994-2001. PubMed ID: 30211830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.